keyword
MENU ▼
Read by QxMD icon Read
search

ustekinumab

keyword
https://www.readbyqxmd.com/read/29776658/ustekinumab-for-refractory-giant-cell-arteritis-a-prospective-52-week-trial
#1
Richard Conway, Lorraine O'Neill, Phil Gallagher, Geraldine M McCarthy, Conor C Murphy, Douglas J Veale, Ursula Fearon, Eamonn S Molloy
OBJECTIVES: Giant cell arteritis (GCA) is the most common form of systemic vasculitis. Glucocorticoids are an effective treatment but have significant adverse events and relapses are common. Interleukins 12 (IL-12) and 23 (IL-23) stimulate TH 1 and TH 17 responses and are implicated in the pathogenesis of GCA. The aim of this study was to evaluate the efficacy and safety of IL-12/23 blockade with ustekinumab in GCA. METHODS: We performed a prospective open label study of ustekinumab in patients with refractory GCA...
April 22, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29776016/psoriasis-area-and-severity-index-pasi-response-in-moderate-severe-psoriatic-patients-switched-to-adalimumab-results-from-the-oppsa-study
#2
M Talamonti, M Galluzzo, N Bernardini, G Caldarola, S Persechino, F Cantoresi, C G Egan, C Potenza, K Peris, L Bianchi
BACKGROUND: Few studies have compared the efficacy of switching to adalimumab in the real-life setting in plaque psoriasis patients. OBJECTIVE: To evaluate the effect of adalimumab in psoriasis patients previously treated with other biologics. METHODS: In this multicentre study, psoriasis patients (N=262) treated with an anti-TNF alpha agent, ustekinumab or naïve to biologics then switched to adalimumab were included. Disease severity was assessed by the Psoriasis Area and Severity Index (PASI) at baseline and after 3, 6, 12, 24 and 36 months...
May 18, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29773231/biologics-in-sapho-syndrome-a-systematic-review
#3
REVIEW
Dimitrios Daoussis, Georgia Konstantopoulou, Pantelis Kraniotis, Lazaros Sakkas, Stamatis-Nick Liossis
BACKGROUND: The SAPHO syndrome is a relatively rare clinical entity characterized by a wide range of dermatological and musculoskeletal manifestations. Biologics have been used in cases refractory to conventional treatment. METHODS: We present herein a patient with refractory to treatment SAPHO syndrome who exhibited a dramatic and fast response to IL-17 blockade. Additionally, we performed a systematic review of all cases of patients with SAPHO syndrome treated with biologics to date...
April 17, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29766731/-current-and-prospective-biologics-and-small-molecules-in-the-treatment-of-inflammatory-bowel-diseases
#4
Milan Buc
Crohns disease (CD) and ulcerative colitis (UC) belong to chronic inflammatory bowel diseases, which are induced by autoimmune processes. While CD is characterized by over-activity of Th1, ILC1, and MAIT cells, UC is mediated by exaggerated activities of Th2 and ILC2 cells and cytokines they produce. Knowledge of the pathogenesis enabled a rational therapy based mostly on biologics and small molecules. TNF is the principal proinflammatory cytokine in both diseases. Anti-TNF monoclonal antibodies, mostly infliximab or adalimumab were therefore introduced to their treatment...
2018: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/29757046/biologic-treatment-of-recalcitrant-pediatric-psoriasis-a-case-series-from-a-tertiary-medical-center
#5
Ayelet Ollech, Alex Zvulunov, Lev Pavlovsky, Emmilia Hodak, Dan Ben Amitai
BACKGROUND: There is a paucity of data on the use of biologic therapy in recalcitrant pediatric psoriasis. The current study presents pediatric psoriasis cases treated with biologic agents in a tertiary referral center. METHODS: In this retrospective case series, data was collected on all patients ≤ 18 years old with severe psoriasis treated with biological therapy from 2010 through 2016 in a tertiary children's hospital. We included demographic data, previous systemic treatments, reason for discontinuation or switch to other systemic treatments, efficacy and side effects...
May 14, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29757042/comparison-of-napsi-and-n-nail-for-evaluation-of-fingernail-psoriasis-in-patients-with-moderate-to-severe-plaque-psoriasis-treated-using-ustekinumab
#6
Bo Ri Kim, Seungkeol Yang, Chong Won Choi, Sang Woong Youn
OBJECTIVE: We sought to determine which psoriatic nail features more effectively respond to ustekinumab treatment and evaluate which between the Nail Psoriasis Severity Index (NAPSI) and the Nijmegen-Nail psoriasis Activity Index tooL (N-NAIL) better reflects the clinical improvement of nail psoriasis. METHODS: Thirty patients with moderate-to-severe plaque psoriasis were prospectively enrolled; the patients were treated with ustekinumab for 52 weeks. A single investigator evaluated the condition using the NAPSI and the N-NAIL with serial fingernail photographs...
May 14, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29750443/s3-guideline-for-the-treatment-of-psoriasis-vulgaris-update-short-version-part-1-systemic-treatment
#7
Alexander Nast, Lasse Amelunxen, Matthias Augustin, Wolf-Henning Boehncke, Corinna Dressler, Matthew Gaskins, Peter Härle, Bernd Hoffstadt, Joachim Klaus, Joachim Koza, Ulrich Mrowietz, Hans-Michael Ockenfels, Sandra Philipp, Kristian Reich, Thomas Rosenbach, Berthold Rzany, Martin Schlaeger, Gerhard Schmid-Ott, Michael Sebastian, Ralph von Kiedrowski, Tobias Weberschock
The German guideline for the treatment of psoriasis vulgaris was updated using GRADE methodology. The guideline is based on a systematic literature review completed on December 1, 2016, and on a formal consensus and approval process. The first section of this short version of the guideline covers systemic treatment options considered relevant by the expert panel and approved in Germany at the time of the consensus conference (acitretin, adalimumab, apremilast, cyclosporine, etanercept, fumaric acid esters, infliximab, methotrexate, secukinumab and ustekinumab)...
May 2018: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/29729105/cost-effectiveness-of-secukinumab-as-first-biologic-treatment-compared-with-other-biologics-for-moderate-to-severe-psoriasis-in-germany
#8
Matthias Augustin, Doreen McBride, Isabelle Gilloteau, Caitriona O'Neill, Katja Neidhardt, Christopher N Graham
BACKGROUND: Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A, has demonstrated strong and sustained efficacy in adults with moderate to severe psoriasis in clinical trials. OBJECTIVE: This analysis compared the cost per responder of secukinumab as first biologic treatment of moderate to severe psoriasis, with adalimumab, infliximab, etanercept, and ustekinumab in Germany. METHODS: A 52-week decision-tree model was developed...
May 5, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29726939/the-effects-of-ustekinumab-on-health-related-quality-of-life-in-patients-with-moderate-to-severe-crohn-s-disease
#9
Bruce E Sands, Chenglong Han, Christopher Gasink, Douglas Jacobstein, Philippe Szapary, Long-Long Gao, Yinghua Lang, Stephan Targan, William J Sandborn, Brian G Feagan
Background and Aims: We assessed the effect of ustekinumab on health-related quality of life (HRQOL) in adults with Crohn's disease (CD). Methods: Patients with moderately-to-severely active CD and inadequate response or intolerance to tumor necrosis factor antagonists (UNITI1, N=741), or conventional therapy (UNITI-2, N=627) were randomized to placebo, ustekinumab 130 mg, or 6 mg/kg intravenous induction therapy. At Week 8, ustekinumab-treated responders (CDAI reduction≥100 or CDAI<150 points) were re-randomized to subcutaneous maintenance therapy (IM-UNITI, N=388) with placebo, ustekinumab 90mg q12w, or q8w for 44 additional weeks...
May 3, 2018: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29717037/the-effect-of-biologic-and-targeted-synthetic-drugs-on-work-and-productivity-related-outcomes-for-patients-with-psoriatic-arthritis-a-systematic-review
#10
Nicolas Iragorri, Mark Hofmeister, Eldon Spackman, Glen S Hazlewood
OBJECTIVE: To systematically review the effects of biologic therapies for psoriatic arthritis [secukinumab, ustekinumab, adalimumab, etanercept, certolizumab pegol (CZP), apremilast, golimumab (GOL), or infliximab (IFX)] on work productivity. METHODS: A systematic review of Medline, EMBASE, CENTRAL, and ClinicalTrials.gov was conducted to identify randomized controlled trials reporting on work productivity outcomes at the end of the placebo-controlled double-blind period...
May 1, 2018: Journal of Rheumatology
https://www.readbyqxmd.com/read/29706309/drug-survival-of-biologic-therapies-for-the-treatment-of-psoriasis-results-of-slovenian-national-registry
#11
Tomaz Lunder, Pij Marko, Natasa Koser Kolar, Boris Kralj, Nada Kecelj Leskovec
The study was designed as observational retrospective analysis of the data from Slovenian Registry of patients with moderate and severe psoriasis treated with adalimumab, etanercept, infliximab or ustekinumab from 2005 to 2015. The survival rates of biologics were compared using survival analysis, and predictors of discontinuation were evaluated using a Cox regression model. All biologics have been prescribed as a first line therapy for moderate or severe psoriasis; 650 (94.9%) adalimumab, 254 (72.0%) ustekinumab, 76 (69...
April 26, 2018: Biologicals: Journal of the International Association of Biological Standardization
https://www.readbyqxmd.com/read/29705819/paradoxical-pustular-psoriasis-induced-by-ustekinumab-in-a-patient-with-crohn-s-disease-associated-spondyloarthropathy
#12
REVIEW
Michael Benzaquen, Benoit Flachaire, Frank Rouby, Philippe Berbis, Sandrine Guis
Palmoplantar pustular psoriasis (PPP) is a clinical form of psoriasis, for which tumor necrosis factor alpha inhibitors (TNFi) or interleukins 12/23 inhibitor (ustekinumab) can be a therapeutic option. Paradoxical psoriatic reactions induced by TNFi are now well known. We present the exceptional case of a paradoxical PPP appeared under ustekinumab in a patient with Crohn's disease-associated spondyloarthropathy. A 58-year-old woman presented with recent peripheral inflammatory arthralgias appeared in the context of a Crohn's disease diagnosed in 2008...
April 28, 2018: Rheumatology International
https://www.readbyqxmd.com/read/29693053/plurifocal-cutaneous-leishmaniasis-during-treatment-with-ustekinumab
#13
Louva Rakotonarivo, Dominique Lons-Danic, Michel Janier
No abstract text is available yet for this article.
May 2018: JAAD Case Reports
https://www.readbyqxmd.com/read/29688479/ustekinumab-treatment-in-crohn-s-disease-of-barnett-continent-intestinal-reservoir
#14
Freeha Khan, Bo Shen
No abstract text is available yet for this article.
April 23, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29683393/usefulness-and-correlation-with-clinical-response-of-serum-ustekinumab-levels-measured-at-6-weeks-versus-12-weeks
#15
M Toro-Montecinos, F Ballescá, C Ferrandiz, A Teniente-Serra, E Martinez-Caceres, J M Carrascosa
BACKGROUND: Monitoring serum drug levels has been proposed as a useful tool for improving and personalising the management of psoriasis. However, in the case of ustekinumab the usefulness of such monitoring was not demonstrated when drug levels were measured at week 12. OBJECTIVES: To evaluate the correlation of serum ustekinumab levels measured at weeks 6 and 12 with clinical response. METHODS: In a prospective cohort study, we enrolled patients with psoriasis treated with ustekinumab 45 mg every 12 weeks for at least 24 weeks...
April 23, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29676599/psoriasis-in-pregnancy-case-series-and-literature-review-of-data-concerning-exposure-during-pregnancy-to-ustekinumab
#16
M Galluzzo, S D'Adamio, L Bianchi, M Talamonti
Psoriasis tends to improve for approximately half of patients during pregnancy, but an equal number of patients report no change or worsening during this period, when lots of medications, like biologics, are not indicated. The aim of our study was to review data of patient that had been pregnant during ustekinumab treatment, analyzing data of our data set between September 2010 and February 2018. We found data of three patients that had been pregnant during ustekinumab treatment. All three patients successfully completed the pregnancy without complications...
April 20, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29676591/a-retrospective-observational-study-on-biological-drug-treatment-in-a-daily-practice-serving-patients-with-psoriasis-in-japan
#17
Chika Ohata, Bungo Ohyama, Aya Nanri, Takako Shintani, Takekuni Nakama
BACKGROUND: In Japan, more than 5 years have passed since emergence of the first 3 biologics, infliximab, adalimumab, and ustekinumab, became available in daily practice; however, no data for drug survival was reported from Japan. OBJECTIVE: To study the long-term drug survival of infliximab, adalimumab, and ustekinumab used for Japanese psoriatic patients. METHODS: We retrieved data on all patients treated with biological agents and calculated the long-term drug survival for infliximab, adalimumab, and ustekinumab using our psoriasis registry (Kurume Psoriasis Registry: KURUPR) consisted of 343 patients by the end of March 2017...
April 20, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29676189/association-between-clinical-factors-and-dose-modification-strategies-in-the-treatment-with-ustekinumab-for-moderate-to-severe-plaque-psoriasis
#18
Rosa M Romero-Jimenez, Vicente Escudero-Vilaplana, Ofelia Baniandres Rodriguez, Estela García Martín, Ana Mateos Mayo, Maria Sanjurjo Saez
PURPOSE: The aim of this study was to identify clinical factors associated with dose reduction and dose escalation in the treatment with ustekinumab in patients with moderate to severe plaque psoriasis. MATERIALS AND METHODS: An observational, longitudinal and retrospective study was conducted using patients with moderate to severe plaque psoriasis. We reviewed clinical histories and variables were recorded on a database (patients' characteristics, pharmacotherapeutics, effectiveness and safety)...
April 20, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29674768/a-case-of-psoriasis-complicated-by-breast-cancer-after-systemic-treatments-including-biologics
#19
Shin Morizane, Saeko Sugimoto, Takayuki Motoki, Norihisa Katayama, Masako Omori, Keiji Iwatsuki
Psoriasis is a common chronic inflammatory skin disorder that is characterized by scaly, erythematous, sharply demarcated plaques. The treatment for psoriasis has dramatically changed over the last 10 years with the introduction of biologics. However, the risk of cancer induced by biologics for psoriasis has not been fully analyzed, since these agents have such a short history of use. Here we report the case of a 74-year-old woman with psoriasis vulgaris and psoriatic arthritis complicated by breast cancer after systemic treatments including etretinate, cyclosporine, methotrexate, adalimumab, and ustekinumab...
April 2018: Acta Medica Okayama
https://www.readbyqxmd.com/read/29668974/ustekinumab-as-an-induction-agent-for-crohn-s-disease-of-the-pouch
#20
Amandeep Singh, Yezaz Ghouri, Bo Shen
No abstract text is available yet for this article.
April 13, 2018: Inflammatory Bowel Diseases
keyword
keyword
34739
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"